XML 16 R2.htm IDEA: XBRL DOCUMENT v3.26.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
Pay versus Performance Disclosure
As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, Quanterix is providing information about the relationship between the compensation of Quanterix’s former principal executive officers (“PEOs”) and other named executive officers and certain Company financial performance measures.
The dollar amounts reported below representing “compensation actually paid” have been calculated in accordance with the requirements of Item 402(v) of Regulation S-K. These figures do not reflect the actual amounts of compensation paid to the officers identified during such fiscal years and are based on equity valuation assumptions required by the SEC, which may not reflect actual amounts realized or realizable at vesting or exercise, as applicable.
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Value of Initial Fixed
$100 Investment
Based On:
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Year
​ ​
Summary
Compensation
Table Total for
E. Kevin
Hrusovsky(1)
($)
​ ​
Summary
Compensation
Table Total for
Masoud
Toloue,
Ph.D.(2)
($)
​ ​
Compensation
Actually Paid
to E. Kevin
Hrusovsky(1)(3)
($)
​ ​
Actually Paid
to Masoud
Toloue,
Ph.D.(2)(3)
($)
​ ​
Average
Summary
Compensation
Table Total
for Non-PEO
NEOs(4)
($)
​ ​
Average
Compensation Actually
Paid to Non-PEO
NEOs(4)(5)
($)
​ ​
Total
Share-
holder
Return
($)
​ ​
Peer
Group
Total
Share-
holder
Return(6)
($)
​ ​
Net
Income
(Loss)
($ in
millions)
​ ​
Revenues
($ in
millions)
​
2025 ​ ​ ​ ​ n/a ​ ​ ​ ​ ​ 5,250,745 ​ ​ ​ ​ ​ n/a ​ ​ ​ ​ ​ 1,312,200 ​ ​ ​ ​ ​ 1,403,916 ​ ​ ​ ​ ​ 2,807,833 ​ ​ ​ ​ ​ 13.68 ​ ​ ​ ​ ​ 124.75 ​ ​ ​ ​ ($ 107.2) ​ ​ ​ ​ ​ 138.9 ​ ​
2024 ​ ​ ​ ​ n/a ​ ​ ​ ​ ​ 6,433,027 ​ ​ ​ ​ ​ n/a ​ ​ ​ ​ ​ 1,346,679 ​ ​ ​ ​ ​ 2,617,523 ​ ​ ​ ​ ​ 1,200,871 ​ ​ ​ ​ ​ 22.86 ​ ​ ​ ​ ​ 93.49 ​ ​ ​ ​ ​ (38.5) ​ ​ ​ ​ ​ 137.4 ​ ​
2023 ​ ​ ​ ​ n/a ​ ​ ​ ​ ​ 5,435,274 ​ ​ ​ ​ ​ n/a ​ ​ ​ ​ ​ 10,859,697 ​ ​ ​ ​ ​ 1,611,175 ​ ​ ​ ​ ​ 3,072,778 ​ ​ ​ ​ ​ 58.80 ​ ​ ​ ​ ​ 94.03 ​ ​ ​ ​ ​ (28.4)* ​ ​ ​ ​ ​ 122.4 ​ ​
2022 ​ ​ ​ ​ 1,921,523 ​ ​ ​ ​ ​ 2,957,026 ​ ​ ​ ​ ​ (3,807,926) ​ ​ ​ ​ ​ 1,699,747 ​ ​ ​ ​ ​ 1,210,719 ​ ​ ​ ​ ​ (470,362) ​ ​ ​ ​ ​ 29.78 ​ ​ ​ ​ ​ 89.90 ​ ​ ​ ​ ​ (99.6)* ​ ​ ​ ​ ​ 105.5 ​ ​
2021 ​ ​ ​ ​ 4,208,194 ​ ​ ​ ​ ​ n/a ​ ​ ​ ​ ​ 7,594,456 ​ ​ ​ ​ ​ n/a ​ ​ ​ ​ ​ 1,495,417 ​ ​ ​ ​ ​ 217,434 ​ ​ ​ ​ ​ 91.18 ​ ​ ​ ​ ​ 100.02 ​ ​ ​ ​ ​ (55.5)* ​ ​ ​ ​ ​ 110.6 ​ ​
​
*
As restated.
(1)
Mr. Hrusovsky served as Chief Executive Officer until April 25, 2022 and as Executive Chairman from April 25, 2022 until August 8, 2022.
​
(2)
Dr. Toloue became President and Chief Executive Officer on April 25, 2022.
​
(3)
The following adjustments were made to the designated PEO’s compensation to calculate the amounts shown as “compensation actually paid” for the periods indicated:
​
Year
​ ​
PEO Name
​ ​
Summary
Compensation
Table Total
($)
​ ​
Less Grant
Date Fair
Value of
Equity Awards
Granted
during
Applicable
Year
($)
​ ​
Plus Year-end
Fair Value of
Equity Awards
Granted
during
Applicable
Year
($)
​ ​
Plus Change
in Fair Value
as of Year-
end of any
Prior Year
Awards that
Remain
Unvested as
of Year-End
($)
​ ​
Plus Change
in Fair Value
as of the
Vesting Date
of any Prior
Year Awards
that Vest
during
Applicable
Year
($)
​ ​
Less Prior Year-
end Fair Value of
Awards Granted
in Prior Year
that Failed to
Meet Vesting
Conditions
during
Applicable Year
($)
​ ​
Total Equity
Value Reflected
in Compensation
Actually Paid
Calculation
($)
​
2025 ​ ​
Masoud Toloue, Ph.D.
​ ​ ​ ​ 5,250,745 ​ ​ ​ ​ ​ 3,899,998 ​ ​ ​ ​ ​ 2,902,256 ​ ​ ​ ​ ​ (2,050,826) ​ ​ ​ ​ ​ 1,734,724 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (3,938,545) ​ ​
2024 ​ ​
Masoud Toloue, Ph.D.
​ ​ ​ ​ 6,433,027 ​ ​ ​ ​ ​ 5,199,987 ​ ​ ​ ​ ​ 2,420,861 ​ ​ ​ ​ ​ (1,990,327) ​ ​ ​ ​ ​ (316,895) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (5,086,348) ​ ​
2023 ​ ​
Masoud Toloue, Ph.D.
​ ​ ​ ​ 5,435,274 ​ ​ ​ ​ ​ 3,999,989 ​ ​ ​ ​ ​ 7,923,070 ​ ​ ​ ​ ​ 1,250,477 ​ ​ ​ ​ ​ 250,865 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 5,424,423 ​ ​
2022 ​ ​
Masoud Toloue, Ph.D.
​ ​ ​ ​ 2,957,026 ​ ​ ​ ​ ​ 1,999,996 ​ ​ ​ ​ ​ 1,234,526 ​ ​ ​ ​ ​ (323,502) ​ ​ ​ ​ ​ (168,307) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (1,257,279) ​ ​
2022 ​ ​ E. Kevin Hrusovsky ​ ​ ​ ​ 1,921,523 ​ ​ ​ ​ ​ 1,400,007 ​ ​ ​ ​ ​ 864,173 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (372,494) ​ ​ ​ ​ ​ 4,821,121 ​ ​ ​ ​ ​ (5,729,449) ​ ​
2021 ​ ​ E. Kevin Hrusovsky ​ ​ ​ ​ 4,208,194 ​ ​ ​ ​ ​ 3,008,520 ​ ​ ​ ​ ​ 1,726,302 ​ ​ ​ ​ ​ 50,554 ​ ​ ​ ​ ​ 4,617,926 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 3,386,262 ​ ​
(4)
The dollar amounts represent the average of the amounts reported for the following named executive officers as a group (excluding Quanterix’s PEOs):
​
​
2021
​ ​
2022
​ ​
2023
​ ​
2024
​ ​
2025
​
​
Masoud Toloue, Ph.D.
​ ​
Michael Doyle
​ ​
Michael Doyle
​ ​
Vandana Sriram
​ ​
Vandana Sriram
​
​
Michael Doyle
​ ​
John Fry
​ ​
Vandana Sriram
​ ​ ​ ​ ​
William P. Donnelly
​
​
Amol Chaubal
​ ​
Mark Roskey, Ph.D.
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
John Fry
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
William Geist
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
Dawn Mattoon
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
Shawn Stetson
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
(5)
The following adjustments were made to calculate the amounts shown as “average compensation actually paid” for the periods indicated:
​
Year
​ ​
NEO Names
​ ​
Summary
Compensation
Table Total
(Average) ($)
​ ​
Less Grant
Date Fair
Value of
Equity Awards
Granted
during
Applicable
Year
(Average)
($)
​ ​
Plus Year-
end Fair
Value of
Equity Awards
Granted
during
Applicable
Year
(Average)
($)
​ ​
Plus Change
in Fair Value
as of Year-
end of any
Prior Year
Awards that
Remain
Unvested as
of Year-End
(Average)
($)
​ ​
Plus Change
in Fair Value
as of the
Vesting Date
of any Prior
Year Awards
that Vest
during
Applicable
Year
(Average)
($)
​ ​
Less Prior
Year-end
Fair Value of
Awards
Granted in
Prior Year
that Failed to
Meet Vesting
Conditions
during
Applicable
Year
(Average)
($)
​ ​
Total Equity
Value Reflected
in Average
Compensation
Actually Paid
Calculation
($)
​
2025 ​ ​
See footnote (4)
​ ​ ​ ​ 1,403,916 ​ ​ ​ ​ ​ 1,913,112 ​ ​ ​ ​ ​ 1,358,816 ​ ​ ​ ​ ​ (492,233) ​ ​ ​ ​ ​ 649,323 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (1,073,606) ​ ​
2024 ​ ​
See footnote (4)
​ ​ ​ ​ 2,617,523 ​ ​ ​ ​ ​ 1,899,992 ​ ​ ​ ​ ​ 884,543 ​ ​ ​ ​ ​ (226,263) ​ ​ ​ ​ ​ (174,940) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (1,416,652) ​ ​
2023 ​ ​
See footnote (4)
​ ​ ​ ​ 1,611,175 ​ ​ ​ ​ ​ 1,150,002 ​ ​ ​ ​ ​ 1,935,392 ​ ​ ​ ​ ​ 589,183 ​ ​ ​ ​ ​ 87,031 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 1,461,603 ​ ​
2022 ​ ​
See footnote (4)
​ ​ ​ ​ 1,210,719 ​ ​ ​ ​ ​ 761,790 ​ ​ ​ ​ ​ 375,346 ​ ​ ​ ​ ​ (118,480) ​ ​ ​ ​ ​ (132,737) ​ ​ ​ ​ ​ 1,043,421 ​ ​ ​ ​ ​ (1,681,081) ​ ​
2021 ​ ​
See footnote (4)
​ ​ ​ ​ 1,495,417 ​ ​ ​ ​ ​ 995,666 ​ ​ ​ ​ ​ 504,941 ​ ​ ​ ​ ​ 3,663 ​ ​ ​ ​ ​ 357,701 ​ ​ ​ ​ ​ 1,148,621 ​ ​ ​ ​ ​ (1,277,982) ​ ​
​
(6)
The peer group used is the NASDAQ Biotechnology Index, our peer group used for purposes of Item 201(e) of Regulation S-K.
       
Company Selected Measure Name Revenues        
Named Executive Officers, Footnote
(1)
Mr. Hrusovsky served as Chief Executive Officer until April 25, 2022 and as Executive Chairman from April 25, 2022 until August 8, 2022.
​
(2)
Dr. Toloue became President and Chief Executive Officer on April 25, 2022.
(4)
The dollar amounts represent the average of the amounts reported for the following named executive officers as a group (excluding Quanterix’s PEOs):
​
​
2021
​ ​
2022
​ ​
2023
​ ​
2024
​ ​
2025
​
​
Masoud Toloue, Ph.D.
​ ​
Michael Doyle
​ ​
Michael Doyle
​ ​
Vandana Sriram
​ ​
Vandana Sriram
​
​
Michael Doyle
​ ​
John Fry
​ ​
Vandana Sriram
​ ​ ​ ​ ​
William P. Donnelly
​
​
Amol Chaubal
​ ​
Mark Roskey, Ph.D.
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
John Fry
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
William Geist
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
Dawn Mattoon
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
Shawn Stetson
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
       
Peer Group Issuers, Footnote
(6)
The peer group used is the NASDAQ Biotechnology Index, our peer group used for purposes of Item 201(e) of Regulation S-K.
       
Adjustment To PEO Compensation, Footnote
(3)
The following adjustments were made to the designated PEO’s compensation to calculate the amounts shown as “compensation actually paid” for the periods indicated:
​
Year
​ ​
PEO Name
​ ​
Summary
Compensation
Table Total
($)
​ ​
Less Grant
Date Fair
Value of
Equity Awards
Granted
during
Applicable
Year
($)
​ ​
Plus Year-end
Fair Value of
Equity Awards
Granted
during
Applicable
Year
($)
​ ​
Plus Change
in Fair Value
as of Year-
end of any
Prior Year
Awards that
Remain
Unvested as
of Year-End
($)
​ ​
Plus Change
in Fair Value
as of the
Vesting Date
of any Prior
Year Awards
that Vest
during
Applicable
Year
($)
​ ​
Less Prior Year-
end Fair Value of
Awards Granted
in Prior Year
that Failed to
Meet Vesting
Conditions
during
Applicable Year
($)
​ ​
Total Equity
Value Reflected
in Compensation
Actually Paid
Calculation
($)
​
2025 ​ ​
Masoud Toloue, Ph.D.
​ ​ ​ ​ 5,250,745 ​ ​ ​ ​ ​ 3,899,998 ​ ​ ​ ​ ​ 2,902,256 ​ ​ ​ ​ ​ (2,050,826) ​ ​ ​ ​ ​ 1,734,724 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (3,938,545) ​ ​
2024 ​ ​
Masoud Toloue, Ph.D.
​ ​ ​ ​ 6,433,027 ​ ​ ​ ​ ​ 5,199,987 ​ ​ ​ ​ ​ 2,420,861 ​ ​ ​ ​ ​ (1,990,327) ​ ​ ​ ​ ​ (316,895) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (5,086,348) ​ ​
2023 ​ ​
Masoud Toloue, Ph.D.
​ ​ ​ ​ 5,435,274 ​ ​ ​ ​ ​ 3,999,989 ​ ​ ​ ​ ​ 7,923,070 ​ ​ ​ ​ ​ 1,250,477 ​ ​ ​ ​ ​ 250,865 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 5,424,423 ​ ​
2022 ​ ​
Masoud Toloue, Ph.D.
​ ​ ​ ​ 2,957,026 ​ ​ ​ ​ ​ 1,999,996 ​ ​ ​ ​ ​ 1,234,526 ​ ​ ​ ​ ​ (323,502) ​ ​ ​ ​ ​ (168,307) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (1,257,279) ​ ​
2022 ​ ​ E. Kevin Hrusovsky ​ ​ ​ ​ 1,921,523 ​ ​ ​ ​ ​ 1,400,007 ​ ​ ​ ​ ​ 864,173 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (372,494) ​ ​ ​ ​ ​ 4,821,121 ​ ​ ​ ​ ​ (5,729,449) ​ ​
2021 ​ ​ E. Kevin Hrusovsky ​ ​ ​ ​ 4,208,194 ​ ​ ​ ​ ​ 3,008,520 ​ ​ ​ ​ ​ 1,726,302 ​ ​ ​ ​ ​ 50,554 ​ ​ ​ ​ ​ 4,617,926 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 3,386,262 ​ ​
       
Non-PEO NEO Average Total Compensation Amount $ 1,403,916 $ 2,617,523 $ 1,611,175 $ 1,210,719 $ 1,495,417
Non-PEO NEO Average Compensation Actually Paid Amount $ 2,807,833 1,200,871 3,072,778 (470,362) 217,434
Adjustment to Non-PEO NEO Compensation Footnote
(5)
The following adjustments were made to calculate the amounts shown as “average compensation actually paid” for the periods indicated:
​
Year
​ ​
NEO Names
​ ​
Summary
Compensation
Table Total
(Average) ($)
​ ​
Less Grant
Date Fair
Value of
Equity Awards
Granted
during
Applicable
Year
(Average)
($)
​ ​
Plus Year-
end Fair
Value of
Equity Awards
Granted
during
Applicable
Year
(Average)
($)
​ ​
Plus Change
in Fair Value
as of Year-
end of any
Prior Year
Awards that
Remain
Unvested as
of Year-End
(Average)
($)
​ ​
Plus Change
in Fair Value
as of the
Vesting Date
of any Prior
Year Awards
that Vest
during
Applicable
Year
(Average)
($)
​ ​
Less Prior
Year-end
Fair Value of
Awards
Granted in
Prior Year
that Failed to
Meet Vesting
Conditions
during
Applicable
Year
(Average)
($)
​ ​
Total Equity
Value Reflected
in Average
Compensation
Actually Paid
Calculation
($)
​
2025 ​ ​
See footnote (4)
​ ​ ​ ​ 1,403,916 ​ ​ ​ ​ ​ 1,913,112 ​ ​ ​ ​ ​ 1,358,816 ​ ​ ​ ​ ​ (492,233) ​ ​ ​ ​ ​ 649,323 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (1,073,606) ​ ​
2024 ​ ​
See footnote (4)
​ ​ ​ ​ 2,617,523 ​ ​ ​ ​ ​ 1,899,992 ​ ​ ​ ​ ​ 884,543 ​ ​ ​ ​ ​ (226,263) ​ ​ ​ ​ ​ (174,940) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (1,416,652) ​ ​
2023 ​ ​
See footnote (4)
​ ​ ​ ​ 1,611,175 ​ ​ ​ ​ ​ 1,150,002 ​ ​ ​ ​ ​ 1,935,392 ​ ​ ​ ​ ​ 589,183 ​ ​ ​ ​ ​ 87,031 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 1,461,603 ​ ​
2022 ​ ​
See footnote (4)
​ ​ ​ ​ 1,210,719 ​ ​ ​ ​ ​ 761,790 ​ ​ ​ ​ ​ 375,346 ​ ​ ​ ​ ​ (118,480) ​ ​ ​ ​ ​ (132,737) ​ ​ ​ ​ ​ 1,043,421 ​ ​ ​ ​ ​ (1,681,081) ​ ​
2021 ​ ​
See footnote (4)
​ ​ ​ ​ 1,495,417 ​ ​ ​ ​ ​ 995,666 ​ ​ ​ ​ ​ 504,941 ​ ​ ​ ​ ​ 3,663 ​ ​ ​ ​ ​ 357,701 ​ ​ ​ ​ ​ 1,148,621 ​ ​ ​ ​ ​ (1,277,982) ​ ​
       
Compensation Actually Paid vs. Total Shareholder Return
Comparison of “Compensation Actually Paid” to our Total Shareholder Return (“TSR”)
Our TSR was $91.8, $29.78, $58.80, $22.86, and $13.68 for the fiscal years ended December 31, 2021, 2022, 2023, 2024, and 2025, respectively. Mr. Hrusovsky’s “compensation actually paid” was $7.6 million and $(3.8) million for the fiscal years ended December 31, 2021, and 2022, respectively, and Dr. Toloue’s
“compensation actually paid” was $1.7 million, $10.9 million, $1.3 million and $1.3 million for the fiscal years ended December 31, 2022, 2023, 2024, and 2025, respectively. The average “compensation actually paid” to our other named executive officers was $0.2 million, $(0.5) million, $3.1 million, $1.2 million, and $2.8 million for the fiscal years ended December 31, 2021, 2022, 2023, 2024 and 2025, respectively. Our TSR decreased from December 31, 2021 to 2022, increased from December 2022 to December 2023 and decreased from December 31, 2023 through December 2025. The “compensation actually paid” to our principal executive officers decreased between 2021 and 2022, increased significantly in 2023, decreased significantly from 2023 to 2024, and decreased in 2025. The average “compensation actually paid” to our other named executive officers decreased between 2021 and 2022, increased significantly in 2023, decreased significantly from 2023 to 2024, and increased in 202.5
       
Compensation Actually Paid vs. Net Income
Comparison of “Compensation Actually Paid” to Net Income (Loss)
Our net loss was approximately $55.5 million in 2021, $99.6 million in 2022, $28.4 million in 2023, $38.5 million in 2024, and $107.2 million in 2025. Mr. Hrusovsky’s “compensation actually paid” was $7.6 million and $(3.8) million for the fiscal years ended December 31, 2021 and 2022, respectively, and Dr. Toloue’s “compensation actually paid” was $1.7 million, $10.9 million, $1.3 million, and $1.3 million for the fiscal years ended December 31, 2022, 2023, 2024 and 2025, respectively. The average “compensation actually paid” to our other named executive officers was $0.2 million, $(0.5) million, $3.1 million, $1.2 million and $2.8 million for the fiscal years ended December 31, 2021, 2022, 2023, 2024 and 2025, respectively. Our net loss increased over the first two years reported, decreased significantly for the third year reported and increased again in both 2024 and 2025, and the “compensation actually paid” to our principal executive officers decreased between 2021 and 2022, increased in 2023, decreased significantly from 2023 to 2024, and decreased slightly in 2025. The average “compensation actually paid” to our other named executive officers decreased between 2021 and 2022, increased significantly in 2023, decreased significantly from 2023 to 2024, and increased in 2025.
       
Compensation Actually Paid vs. Company Selected Measure
Comparison of “Compensation Actually Paid” to Company-Selected Measure (Revenues)
Our revenues were approximately $110.6 million in 2021, $105.5 million in 2022, $122.4 million in 2023, $137.4 million in 2024 and $138.9 million in 2025. Mr. Hrusovsky’s “compensation actually paid” was $7.6 million and $(3.8) million for the fiscal years ended December 31, 2021, and 2022, respectively, and Dr. Toloue’s “compensation actually paid” was $1.7 million, $10.9 million, $1.3 million and $1.3 million for the fiscal years ended December 31, 2022, 2023, 2024 and 2025, respectively. The average “compensation actually paid” to our other named executive officers was $0.2 million, $(0.5) million, $3.1 million, $1.2 and $2.8 million for the fiscal years ended December 31, 2021, 2022, 2023, 2024 and 2025, respectively. Our revenues decreased 5% from 2021 to 2022, increased by 16% from 2022 to 2023, increased by 12% from 2023 to 2024 and increased by 1% from 2024 to 2025, and “compensation actually paid” to our principal executive officers decreased between 2021 and 2022, significantly increased in 2023, decreased significantly from 2023 to 2024 and decreased slightly in 2025. The average “compensation actually paid” to our other named executive officers decreased between 2021 and 2022, increased significantly in 2023, decreased significantly from 2023 to 2024, and increased in 2025.
       
Total Shareholder Return Vs Peer Group
TSR versus Peer Group TSR
The graph below shows our cumulative TSR over the five-year period ended December 31, 2025, as compared to that of the NASDAQ Biotechnology Index.
TOTAL SHAREHOLDER RETURN*
Between Quanterix Corporation
and the NASDAQ Biotechnology Index
[MISSING IMAGE: lc_cumulative-bw.jpg]
​
*
$100 invested on 12/31/20 in stock or index, including reinvestment of dividends. Fiscal year ended December 31.
       
Tabular List, Table
Most Important Financial and Other Performance Measures
We have identified the following financial and other performance measures as being the most important in linking actual compensation paid to executives to our performance for the most recently completed fiscal year:
1.
Revenues
​
2.
Non-GAAP gross margin
​
3.
Strategic objectives
       
Total Shareholder Return Amount $ 13.68 22.86 58.8 29.78 91.18
Peer Group Total Shareholder Return Amount 124.75 93.49 94.03 89.9 100.02
Net Income (Loss) $ (107,200,000) $ (38,500,000) $ (28,400,000) $ (99,600,000) $ (55,500,000)
Company Selected Measure Amount 138,900,000 137,400,000 122,400,000 105,500,000 110,600,000
PEO Name Dr. Toloue        
Measure:: 1          
Pay vs Performance Disclosure          
Name Revenues        
Measure:: 2          
Pay vs Performance Disclosure          
Name Non-GAAP gross margin        
Measure:: 3          
Pay vs Performance Disclosure          
Name Strategic objectives        
Masoud Toloue[Member]          
Pay vs Performance Disclosure          
PEO Total Compensation Amount $ 5,250,745 $ 6,433,027 $ 5,435,274 $ 2,957,026  
PEO Actually Paid Compensation Amount 1,312,200 1,346,679 10,859,697 1,699,747  
E. Kevin Hrusovsky [Member]          
Pay vs Performance Disclosure          
PEO Total Compensation Amount       1,921,523 $ 4,208,194
PEO Actually Paid Compensation Amount       (3,807,926) 7,594,456
PEO | Masoud Toloue[Member] | Equity Awards Adjustments          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (3,938,545) (5,086,348) 5,424,423 (1,257,279)  
PEO | Masoud Toloue[Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (3,899,998) (5,199,987) (3,999,989) (1,999,996)  
PEO | Masoud Toloue[Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 2,902,256 2,420,861 7,923,070 1,234,526  
PEO | Masoud Toloue[Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (2,050,826) (1,990,327) 1,250,477 (323,502)  
PEO | Masoud Toloue[Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,734,724 (316,895) 250,865 (168,307)  
PEO | Masoud Toloue[Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount  
PEO | E. Kevin Hrusovsky [Member] | Equity Awards Adjustments          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount       (5,729,449) 3,386,262
PEO | E. Kevin Hrusovsky [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount       (1,400,007) (3,008,520)
PEO | E. Kevin Hrusovsky [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount       864,173 1,726,302
PEO | E. Kevin Hrusovsky [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount       50,554
PEO | E. Kevin Hrusovsky [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount       (372,494) 4,617,926
PEO | E. Kevin Hrusovsky [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount       (4,821,121)
Non-PEO NEO | Equity Awards Adjustments          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,073,606) (1,416,652) 1,461,603 (1,681,081) (1,277,982)
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,913,112) (1,899,992) (1,150,002) (761,790) (995,666)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,358,816 884,543 1,935,392 375,346 504,941
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (492,233) (226,263) 589,183 (118,480) 3,663
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 649,323 (174,940) 87,031 (132,737) 357,701
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (1,043,421) $ (1,148,621)